Walt Disney Co vs BIO-TECHNE Corp — how do they compare? Walt Disney Co trades at $107.09 (market cap $180.87B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Walt Disney Co is far larger — about 15.9× BIO-TECHNE Corp's market cap, and Walt Disney Co pays the higher dividend (1.43%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and BIO-TECHNE Corp for 63 Days on average.
| DIS | TECH | |
|---|---|---|
Market Cap | $180.87B | $11.37B |
Volume | 7,385,182 | 3,153,511 |
Sector | Media | Health |
52-Week High | $116.65 | $72.61 |
52-Week Low | $92.40 | $43.31 |
Typical Hold Time | 199 Days | 63 Days |
Enterprise Value | $221.73B | $11.40B |
Dividend Yield | 1.43% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.93% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $91.4B to $94.4B in 2025 and net income surging to $12.4B. Recent earnings beats and a $60B parks investment highlight strategic expansion. Analyst consensus remains strongly positive with a $125.67 price target, representing 17% upside potential from current levels.
Disney presents a compelling investment opportunity with accelerating profitability and strategic investments in experiences and streaming. Key risks include free cash flow pressure from elevated capital expenditures and competitive streaming landscape challenges. The stock's current valuation at 21.6x P/E appears reasonable given growth trajectory, though execution on content investments and margin expansion will be critical for sustained outperformance.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →